Blogs

  • Blog

Categories

    AEVOLVE, AG Partners with MPECT Inc. to Provide Healthcare Innovators with Proactive Global Compliance Support
    in

    All,  Health,  Innovations

    Ava

    Tom Martin

    ATLANTA, Sept. 24, 2019 /PRNewswire/ — AEVOLVE, AG, a new firm using the blockchain investment platform to support innovative medical research announced today that it has established a strategic partnership with MPECT, Inc., a pioneer in the use of Cloud computing, Artificial Intelligence and data analytics to provide those in the healthcare sector with constantly evolving compliance and regulatory information and systems.

    New Blockchain Models for Medical Financing: Why Aevolve is at the Forefront
    in

    All,  Avex,  Blockchain,  Health,  Innovations

    Ava

    admin

    Burdened by declining productivity and innovation, biopharma is seeking new ways of financing its growing needs. According to the Tufts Center for the study of Drug Development (CSDD), the cost to develop a new prescription drug is pegged at $2.6 billion. This marks a 145% increase from 2003 estimates, according to an article republished on Scientific American.

    New Research Into Rare Diseases To Be Supported by Aevolve
    in

    All,  Blockchain,  Health,  Innovations

    Ava

    admin

    Rogelio Santos, Jr., CEO of Aevolve, a new platform dedicated to supporting innovative medical research, recently commented on the disturbing gap that exists between the millions of people who have been diagnosed with a rare disease and the life-saving medical treatment they are currently lacking. “Shockingly, 95% of all rare diseases today have absolutely no treatment.

    Million-Dollar Drugs: Encouraging News for Patients with Rare Diseases, But at What Cost?
    in

    All,  Blockchain,  Health,  Innovations

    Ava

    admin

    In recent years, there has been some good news for many of the 30 million people in the U.S. diagnosed with a rare disease, in the form of long-awaited treatment for a number of specific conditions — but this progress has come at a staggering cost for these prescription medications. Fortunately, a new company focusing on life sciences — AEVOLVE AG — has a plan to support medical research that will benefit millions of others with rare diseases, without the alarming costs that are currently associated with drugs of this kind.